The 7,111-patient trial that was presented Tuesday at the American College of Rheumatology's annual meeting in San Antonio, and is part of the Merck's application for approval.
The European Medicines Agency said Friday it has been asked by the European Commission to conduct a review of certain arthritis drugs following the worldwide withdrawal of Merck & Co.'s Vioxx medication.
Most analysts and doctors were expecting the FDA to seek additional information before approving Arcoxia because Merck pulled Vioxx from the market last month after a study showed it doubled patients risk of heart attacks and strokes.
